Dianlong Jia

Shandong Key Laboratory Of Applied Technology For Protein And Peptide Drugs
Liaocheng, 252000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

An EGFR-directed photoimmunotheranostic conjugate enables tumor-specific imaging and potent synergistic antitumor activity.

An EGFR-directed photoimmunotheranostic conjugate enables tumor-specific imaging and potent synergistic antitumor activity.

Journal: Journal of photochemistry and photobiology. B, Biology

Published: March 09, 2026

Development of an active loading strategy for methylene blue in liposomes and its application in EGFR-targeted photodynamic therapy.

Development of an active loading strategy for methylene blue in liposomes and its application in EGFR-targeted photodynamic therapy.

Journal: Journal of pharmaceutical sciences

Published: December 21, 2025

Engineered PD-L1-targeted multifunctional proteins with self-prolonged circulation for enhanced tumor photothermal-immunotherapy.

Engineered PD-L1-targeted multifunctional proteins with self-prolonged circulation for enhanced tumor photothermal-immunotherapy.

Journal: Materials today. Bio

Published: September 09, 2025

A novel EGFR-targeted photosensitizer for the theranostics of skin cancer.

A novel EGFR-targeted photosensitizer for the theranostics of skin cancer.

Journal: International journal of pharmaceutics: X

Published: July 02, 2025

Correction to "Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors".

Correction to "Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors".

Journal: Molecular pharmaceutics

Published: February 07, 2025

Corrigendum to "Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models" [Int. J. Pharm. 586 (2020) 119541].

Corrigendum to "Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models" [Int. J. Pharm. 586 (2020) 119541].

Journal: International journal of pharmaceutics

Published: January 14, 2025

Improving Targeted Delivery and Antitumor Efficacy of TRAIL through Fusion with a B7H3-Antagonistic Affibody.

Improving Targeted Delivery and Antitumor Efficacy of TRAIL through Fusion with a B7H3-Antagonistic Affibody.

Journal: Molecular pharmaceutics

Published: December 02, 2024

TMEM176B inhibits ovarian cancer progression by regulating EMT via the Wnt/β-catenin signaling pathway.

TMEM176B inhibits ovarian cancer progression by regulating EMT via the Wnt/β-catenin signaling pathway.

Journal: Journal of translational medicine

Published: August 29, 2024

ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy.

ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy.

Journal: International journal of biological macromolecules

Published: March 13, 2024

Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes.

Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes.

Journal: Pharmaceutical development and technology

Published: January 17, 2024

Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors.

Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors.

Journal: Molecular pharmaceutics

Published: May 03, 2023

Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.

Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: April 06, 2023

Showing 1-12 of 30

Last Updated: 09/26/2026